2 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Fianlimab: new trials by email Literature Review of Fianlimab trials Research Report on Fianlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-12-01 | 2026-11-03 |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments Linvoseltamab, Daratumumab, Carfilzomib - Multiple Myeloma | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 317 | 2022-08-17 | 2026-11-05 |
| Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer Degarelix, pTVG-AR, Nivolumab - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Wisconsin, Madison | 57 | 2021-12-16 | 2026-09-30 |
| Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies Cemiplimab, Ipilimumab, Platinum-doublet chemotherapy - Advanced Malignancies | Phase 1 | Active not recruiting | Regeneron Pharmaceuticals | 146 | 2017-06-21 | 2026-02-12 |
| Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers REGN3767, cemiplimab - Malignancies | Phase 1 | Completed | Regeneron Pharmaceuticals | 333 | 2016-11-07 | 2024-05-01 |
Multiple Myeloma (1) · Nasopharyngeal Carcinoma (1) · Nasopharyngeal Neoplasms (1) · Neoplasms (1) · Prostatic Neoplasms (1)
Regeneron Pharmaceuticals (3) · Memorial Sloan Kettering Cancer Center (1) · University of Wisconsin, Madison (1)
United States (4) · Australia (1) · France (1) · Greece (1) · Ireland (1) · Israel (1) · Japan (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Douglas McNeel, MD (1) · Nancy Lee, MD (1)
PMID 33146741, PMID 38900987, PMID 39422598, PMID 41781018
2016 (1), 2023 (1), P50CA269011 (1)